What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
Ryerson Holding (NYSE: RYI) finalises Olympic Steel acquisition as North American metals consolidation accelerates
Vikran Engineering (NSE: VIKRAN) Q3 FY26 results show solar-led order book surge as margins reset during execution ramp-up
Ducon Infratechnologies (NSE: DUCON) Q3 FY26 results signal margin pressure even as carbon capture and AI bets move closer to execution
Read More 7 minute read Pharma Industry News GSK to acquire RAPT Therapeutics in strategic push into long-acting food allergy biologics GSK to acquire RAPT Therapeutics for $2.2B, targeting food allergy breakthroughs with ozureprubart. Find out how this changes its immunology strategy. byVenkateshJanuary 21, 2026